Evidence map›Paper›PMID 39595427›Full record

ArticleHealthcare (Basel, Switzerland)2024

Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa.

Christina Due, Jennifer Quinn, Paul Gissen, Angela Schulz, Nicola Specchio, Emily de Los Reyes, Thomas Butt

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christina DueBioMarin International Ltd., London WC1A 2SL, UK.
Jennifer QuinnDebiopharm Inc., 1006 Lausanne, Switzerland.
Paul GissenNational Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, University College London, London WC1N 1EH, UK.ORCID 0000-0002-9712-6122
Angela SchulzDepartment of Pediatrics, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
Nicola SpecchioNeurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Childrens Hospital, IRCCS, European Reference Network EpiCARE, 00165 Rome, Italy.
Emily de Los ReyesNationwide Children's Hospital, Columbus, OH 43205, USA.
Thomas ButtBioMarin International Ltd., London WC1A 2SL, UK.ORCID 0000-0002-0387-4550

Funding

BioMarin Pharmaceutical Inc. No grant number
6 · The paper itself

Abstract

objectivesThis study evaluated the psychometric properties of the ceroid lipofuscinosis type 2 Quality of Life (CLN2 QoL) questionnaire.

methodsData from children with CLN2 disease aged 3-16 years receiving cerliponase alfa in the BMN 190-201 and BMN 190-202 clinical studies, collected via purposive sampling, were used to assess convergent and divergent validity, internal consistency and reliability. The clinically important difference (CID) was estimated with distribution- and anchor-based methods. Descriptive and inferential statistical analyses were conducted using IBM SPSS.

resultsCLN2 QoL data of 22 participants were analysed. Ceiling effects were observed in 22 items (35% threshold); no floor effects were observed. Internal consistency analysis showed good reliability (Cronbach's alpha and Omega reliability >0.7) for four domains at study completion; only one domain had good reliability at baseline. All domains had good test-retest reliability (correlation >0.5) except Feeding With G-Tube and Seizures. Convergent and divergent correlation analysis showed moderate-strong correlations (>0.4) between PedsQL and CLN2 QoL total scores, between the Pediatric Quality of Life Inventory (PedsQL) total score and most CLN2 QoL domains at baseline, and between CLN2 QoL total score and most PedsQL domains at week 97. Known groups validity showed a significant difference in means for the Behaviour domain (

conclusionsThis study is the first to validate the CLN2 QoL and to estimate the CID of this instrument in CLN2 patients. Our results show good validity and reliability of this tool.

Indexed as

clinically important differenceCLN2CLN2 QoLpsychometric testingquality of life

Identifiers

PMID39595427
PMCPMC11593549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.